Praxis Precision Medicines has reported a 56.3% median reduction in seizure frequency from baseline in a midphase trial, encouraging the biotech to push ahead with phase 2/3 plans despite almost a ...

Positive results from a mid-stage study apparently weren’t enough to raise investor confidence in Praxis Precision Medicines ...

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) stock experienced a volatile trading session on Monday, after the company ...

Praxis Precision Medicines' vormatrigine shows promise in epilepsy with 56.3% seizure reduction. Click here to find out why I ...

Praxis’ vormatrigine reduced seizures by 56.3%, an effect size that, according to analysts at Truist Securities, exceeds that ...

RADIANT study with vormatrigine in focal onset seizure (FOS) patients over eight weeks demonstrated 56.3% median reduction in ...

Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) soared 27% on Monday after the company released encouraging top-line ...

Praxis Precision Medicines’ oral vormatrigine stopped 100% of seizures in 22% of patients in a Phase II trial. The RADIANT ...

"It’ s an incredibly exciting time for Praxis and our epilepsy portfolio, as we share updates from first-in-patient and Phase 2 studies for elsunersen, PRAX -562 and PRAX -628," said Marcio ...